<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064166</url>
  </required_header>
  <id_info>
    <org_study_id>PN-1</org_study_id>
    <nct_id>NCT02064166</nct_id>
  </id_info>
  <brief_title>Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.</brief_title>
  <official_title>A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Novak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson disease (PD) and multiple system atrophy (MSA) are progressive neurodegenerative
      disorders characterized by abnormal accumulation of Î±-synuclein. There is no effective
      treatment that can slow down the disease progression and both disorders are associated with
      severe cognitive decline. It was shown that intranasal insulin (INI) improves learning and
      memory in healthy and cognitively impaired non-diabetic adults.

      The proof-of-concept, randomized, placebo-controlled, cross-over pilot study ( NCT01206322)
      has shown that a single 40 international units dose of intranasal insulin improves
      visuospatial memory in diabetes and control subjects.

      This proposal includes randomized, double blinded, placebo-controlled trial of intranasal
      insulin (40 international units daily) in treatment of PD and MSA.

      The study will evaluate 22 patients with PD and 22 patients with MSA. Total duration of the
      study will be 2 years. The primary goal is to assess the efficacy of INI in treatment of
      cognitive abnormalities in both PD and MSA. The primary efficacy end point will be change of
      the cognitive scale ratings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Verbal Fluency FAS (F, A or S Words) Total Score</measure>
    <time_frame>Baseline and post-treatment</time_frame>
    <description>Changes in Verbal Fluency FAS (a total number of F, A or S words) generated after 4 weeks of treatment compared to baseline, FAS total score is a sum of F,A, and S raw scores. The verbal fluency FAS test is used to assess phonemic fluency and verbal memory. Participants are asked to name words starting with letters F, A and S over one minute interval. The unit is a on scale, the normative data are adjusted for age and sex. The higher score means better verbal fluency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Hoehn and Yahr Scale</measure>
    <time_frame>Baseline and post-treatment</time_frame>
    <description>The modified Hoehn and Yahr Scale (HY) is used to assess severity of Parkinson Disease and treatment response post treatment as compared to baseline. The scale ranges from 1 to 5. The lower score indicates better outcome, e.g. less severe parkinsonism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment Using Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Baseline and post-treatment</time_frame>
    <description>The Montreal Cognitive Assessment (MoCA) is a one-page 30-point test administered in approximately 10 minutes and is used to assess symptoms of cognitive impairment and their changes after treatment as compared to baseline. MoCA scores range between 0 and 30 with higher scores indicative of better cognitive performance. A score of 26 and above is considered to be normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory Score (BDI)</measure>
    <time_frame>Baseline and post-treatment</time_frame>
    <description>Beck Depression Inventory (BDI) is a 21-items self reported inventory with a scale evaluating depressive symptoms and the changes in BDI after treatment compared to baseline. The range of scores is 0 to 63, with higher scores indicating greater severity of depression.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Unified Parkinson's Disease Rating Scale Part III (UPDRS Part III)</measure>
    <time_frame>Baseline and post-treatment</time_frame>
    <description>UPDRS Part III has 14 items assessing motor skills including facial expression and speech, tremors, rigidity, posture, gait, and bradykinesia. Left and right sides (arms, legs, and hands) are assessed separately for seven of the functions. The total score for subscale 3 ranges from 0 to 108 (the sum of scores from 14 items with 27 observations). The higher the value, the more severe the symptoms. The outcomes reflect the UPDRS Part III score at baseline and 4 weeks post treatment with post treatment scores compared to baseline in the insulin and placebo groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gait Analysis (4-meter Test)</measure>
    <time_frame>Baseline and post-treatment</time_frame>
    <description>Changes in gait compared to baseline. Data are reported as changes in average stride interval ( inch) at baseline and post treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Brief Visuospatial Memory Test-Revised (BVMT-R)</measure>
    <time_frame>Baseline and post-treatment</time_frame>
    <description>Changes in Brief Visuospatial Memory Test-Revised (BMVT-R) compared to baseline. For BVMT, there were concerns about the test administration and validity of this test which relies on fine motor control in PD patients that have motor impairment which could affect the drawing precision. Therefore, BVMT was not included in the analyses, because these methodological concerns would have affected the calculation of the total score as the outcome measure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of intranasal insulin daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm using intranasal normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Insulin</intervention_name>
    <description>treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;
placebo arm: normal saline, daily, intranasally, for 4 weeks.</description>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Novolin R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females older than 17 years.

          2. Clinical diagnosis of Parkinson disease or multiple system atrophy.

          3. Provide written informed consent to participate in the study.

          4. Understand that they may withdraw their consent at any time.

        Exclusion Criteria:

          1. Women who are pregnant or lactating.

          2. In the investigator's opinion, have significant systemic, hepatic, cardiovascular,
             renal or other illness that can interfere based on investigator judgment with the
             trial.

          3. History of dementia.

          4. Unable to walk without help for at least 1 minute.

          5. History of allergic reaction to insulin.

          6. The presence of inflammation of nasal cavity that may prevents absorption of insulin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Novak`, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Former Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <results_first_submitted>May 23, 2018</results_first_submitted>
  <results_first_submitted_qc>November 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2018</results_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Peter Novak</investigator_full_name>
    <investigator_title>Former Faculty member</investigator_title>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>Multiple system atrophy</keyword>
  <keyword>Intranasal</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Insulin</title>
          <description>Treatment arm: 40 IU of intranasal human insulin Novolin R, Novo Nordisk daily
Intranasal Insulin: Insulin, 40 IU of daily, intranasally, for 4 weeks;</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo arm using intranasal normal saline
Placebo arm: normal saline, daily, intranasally, for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin</title>
          <description>40 IU of intranasal insulin daily
Intranasal Insulin: 1.treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks; 2. placebo arm: normal saline, daily, intranasally, for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo arm using intranasal normal saline
Intranasal Insulin: 1.treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks; 2. placebo arm: normal saline, daily, intranasally, for 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="5.7"/>
                    <measurement group_id="B2" value="62.2" spread="9.6"/>
                    <measurement group_id="B3" value="62.9" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Verbal Fluency FAS (F, A or S Words) Total Score</title>
        <description>Changes in Verbal Fluency FAS (a total number of F, A or S words) generated after 4 weeks of treatment compared to baseline, FAS total score is a sum of F,A, and S raw scores. The verbal fluency FAS test is used to assess phonemic fluency and verbal memory. Participants are asked to name words starting with letters F, A and S over one minute interval. The unit is a on scale, the normative data are adjusted for age and sex. The higher score means better verbal fluency.</description>
        <time_frame>Baseline and post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Baseline</title>
            <description>FAS score in the insulin group at baseline Treatment arm: 40 IU of intranasal human insulin Novolin R, Novo Nordisk daily Intranasal Insulin: Insulin, 40 IU of daily, intranasally, for 4 weeks;</description>
          </group>
          <group group_id="O2">
            <title>Insulin Post Treatment</title>
            <description>FAS score in the insulin group post treatment
Treatment arm: 40 IU of intranasal human insulin Novolin R, Novo Nordisk daily Intranasal Insulin: Insulin, 40 IU of daily, intranasally, for 4 weeks;</description>
          </group>
          <group group_id="O3">
            <title>Placebo Baseline</title>
            <description>FAS score in the placebo group at baseline Placebo arm using intranasal normal saline
Placebo arm: normal saline, daily, intranasally, for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Post Treatment</title>
            <description>FAS score in the placebo group post treatment Placebo arm using intranasal normal saline Placebo arm: normal saline, daily, intranasally, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Verbal Fluency FAS (F, A or S Words) Total Score</title>
          <description>Changes in Verbal Fluency FAS (a total number of F, A or S words) generated after 4 weeks of treatment compared to baseline, FAS total score is a sum of F,A, and S raw scores. The verbal fluency FAS test is used to assess phonemic fluency and verbal memory. Participants are asked to name words starting with letters F, A and S over one minute interval. The unit is a on scale, the normative data are adjusted for age and sex. The higher score means better verbal fluency.</description>
          <units>Words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="5.7"/>
                    <measurement group_id="O2" value="41.0" spread="8.2"/>
                    <measurement group_id="O3" value="32.8" spread="2.3"/>
                    <measurement group_id="O4" value="30.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Hoehn and Yahr Scale</title>
        <description>The modified Hoehn and Yahr Scale (HY) is used to assess severity of Parkinson Disease and treatment response post treatment as compared to baseline. The scale ranges from 1 to 5. The lower score indicates better outcome, e.g. less severe parkinsonism.</description>
        <time_frame>Baseline and post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Baseline</title>
            <description>HY Scale in the insulin group at baseline</description>
          </group>
          <group group_id="O2">
            <title>Insulin Post Treatment</title>
            <description>HY scale in the insulin group post treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo Baseline</title>
            <description>HY scale in placebo group at baseline</description>
          </group>
          <group group_id="O4">
            <title>Placebo Post Treatment</title>
            <description>HY scale in placebo group post treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Hoehn and Yahr Scale</title>
          <description>The modified Hoehn and Yahr Scale (HY) is used to assess severity of Parkinson Disease and treatment response post treatment as compared to baseline. The scale ranges from 1 to 5. The lower score indicates better outcome, e.g. less severe parkinsonism.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.6"/>
                    <measurement group_id="O2" value="2.0" spread="0.7"/>
                    <measurement group_id="O3" value="2.4" spread="0.38"/>
                    <measurement group_id="O4" value="2.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Impairment Using Montreal Cognitive Assessment (MoCA)</title>
        <description>The Montreal Cognitive Assessment (MoCA) is a one-page 30-point test administered in approximately 10 minutes and is used to assess symptoms of cognitive impairment and their changes after treatment as compared to baseline. MoCA scores range between 0 and 30 with higher scores indicative of better cognitive performance. A score of 26 and above is considered to be normal.</description>
        <time_frame>Baseline and post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Baseline</title>
            <description>MOCA Scale in insulin group at baseline</description>
          </group>
          <group group_id="O2">
            <title>Insulin Post Treatment</title>
            <description>MOCA scale in insulin group post treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo Baseline</title>
            <description>MOCA score in the placebo group at baseline</description>
          </group>
          <group group_id="O4">
            <title>Placebo Post Treatment</title>
            <description>MOCA score in the placebo group post treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Impairment Using Montreal Cognitive Assessment (MoCA)</title>
          <description>The Montreal Cognitive Assessment (MoCA) is a one-page 30-point test administered in approximately 10 minutes and is used to assess symptoms of cognitive impairment and their changes after treatment as compared to baseline. MoCA scores range between 0 and 30 with higher scores indicative of better cognitive performance. A score of 26 and above is considered to be normal.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="1.2"/>
                    <measurement group_id="O2" value="28.0" spread="1.1"/>
                    <measurement group_id="O3" value="26.8" spread="2.6"/>
                    <measurement group_id="O4" value="28.2" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory Score (BDI)</title>
        <description>Beck Depression Inventory (BDI) is a 21-items self reported inventory with a scale evaluating depressive symptoms and the changes in BDI after treatment compared to baseline. The range of scores is 0 to 63, with higher scores indicating greater severity of depression.</description>
        <time_frame>Baseline and post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Baseline</title>
            <description>BDI Scale in the insulin group at baseline</description>
          </group>
          <group group_id="O2">
            <title>Insulin Post Treatment</title>
            <description>BDI scale in the insulin group post-treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo Baseline</title>
            <description>BDI score in the placebo group at baseline</description>
          </group>
          <group group_id="O4">
            <title>Placebo Post Treatment</title>
            <description>BDI score in the placebo group post treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory Score (BDI)</title>
          <description>Beck Depression Inventory (BDI) is a 21-items self reported inventory with a scale evaluating depressive symptoms and the changes in BDI after treatment compared to baseline. The range of scores is 0 to 63, with higher scores indicating greater severity of depression.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="5.4"/>
                    <measurement group_id="O2" value="8.25" spread="8.1"/>
                    <measurement group_id="O3" value="13.5" spread="5.6"/>
                    <measurement group_id="O4" value="12.8" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Unified Parkinson's Disease Rating Scale Part III (UPDRS Part III)</title>
        <description>UPDRS Part III has 14 items assessing motor skills including facial expression and speech, tremors, rigidity, posture, gait, and bradykinesia. Left and right sides (arms, legs, and hands) are assessed separately for seven of the functions. The total score for subscale 3 ranges from 0 to 108 (the sum of scores from 14 items with 27 observations). The higher the value, the more severe the symptoms. The outcomes reflect the UPDRS Part III score at baseline and 4 weeks post treatment with post treatment scores compared to baseline in the insulin and placebo groups.</description>
        <time_frame>Baseline and post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Baseline</title>
            <description>UPDRS III Scale in the insulin group at baseline</description>
          </group>
          <group group_id="O2">
            <title>Insulin Post Treatment</title>
            <description>UPDRS III Scale in the insulin group at post treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo Baseline</title>
            <description>UPDRS III Scale in the placebo group at baseline</description>
          </group>
          <group group_id="O4">
            <title>Placebo Post Treatment</title>
            <description>UPDRS III Scale in the insulin group post treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale Part III (UPDRS Part III)</title>
          <description>UPDRS Part III has 14 items assessing motor skills including facial expression and speech, tremors, rigidity, posture, gait, and bradykinesia. Left and right sides (arms, legs, and hands) are assessed separately for seven of the functions. The total score for subscale 3 ranges from 0 to 108 (the sum of scores from 14 items with 27 observations). The higher the value, the more severe the symptoms. The outcomes reflect the UPDRS Part III score at baseline and 4 weeks post treatment with post treatment scores compared to baseline in the insulin and placebo groups.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="20.0"/>
                    <measurement group_id="O2" value="25.6" spread="21.8"/>
                    <measurement group_id="O3" value="31.7" spread="13.3"/>
                    <measurement group_id="O4" value="30.5" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gait Analysis (4-meter Test)</title>
        <description>Changes in gait compared to baseline. Data are reported as changes in average stride interval ( inch) at baseline and post treatment.</description>
        <time_frame>Baseline and post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Baseline</title>
            <description>Stride interval in the insulin group at baseline</description>
          </group>
          <group group_id="O2">
            <title>Insulin Post Treatment</title>
            <description>Stride interval in the insulin group post treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo Baseline</title>
            <description>Stride interval in placebo group at baseline</description>
          </group>
          <group group_id="O4">
            <title>Placebo Post Treatment</title>
            <description>Stride interval in placebo group post treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Gait Analysis (4-meter Test)</title>
          <description>Changes in gait compared to baseline. Data are reported as changes in average stride interval ( inch) at baseline and post treatment.</description>
          <units>inch</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="5.0"/>
                    <measurement group_id="O2" value="21.5" spread="4.4"/>
                    <measurement group_id="O3" value="21.0" spread="2.7"/>
                    <measurement group_id="O4" value="19.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Brief Visuospatial Memory Test-Revised (BVMT-R)</title>
        <description>Changes in Brief Visuospatial Memory Test-Revised (BMVT-R) compared to baseline. For BVMT, there were concerns about the test administration and validity of this test which relies on fine motor control in PD patients that have motor impairment which could affect the drawing precision. Therefore, BVMT was not included in the analyses, because these methodological concerns would have affected the calculation of the total score as the outcome measure.</description>
        <time_frame>Baseline and post-treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Insulin</title>
          <description>40 IU of intranasal insulin daily Intranasal Insulin: 1.treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks; 2. placebo arm: normal saline, daily, intranasally, for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo arm using intranasal normal saline Intranasal Insulin: 1.treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks; 2. placebo arm: normal saline, daily, intranasally, for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Novak, MD PhD</name_or_title>
      <organization>Brigham &amp; Women's Hospital</organization>
      <phone>617-732-8896</phone>
      <email>pnovak2@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

